Skip to main content
OpenTrials
Completed

NCT Number: NCT05671874

Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI

The goal is to pilot test a highly accessible, web-based, pragmatic, scalable intervention to overcome ongoing problems with high stakes decision-making by surrogate decision-makers of patients in ICUs with severe acute brain injury (SABI), including those with moderate-severe traumatic brain injury, large hemispheric acute ischemic stroke and intracerebral hemorrhage.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

Loading trial locations.

About this study

Every 30 seconds an adult in the U.S. suffers a severe acute brain injury (SABI) from traumatic brain injury or large ischemic or hemorrhagic stroke, resulting in 200,000 deaths and >900,000 survivors living with disability annually. Every day, surrogate decision-makers face the difficult "goals of care" decision in intensive care units (ICUs) to continue or withdraw life support while considering the patient's long-term prognosis. In this study, we will pilot test a pragmatic, scalable intervention to overcome ongoing problems with high stakes decision-making by surrogates of patients with SABI in ICUs. These problems are an important target for intervention, because they contribute to 3 major clinical and public health issues: 1) family members struggle in the role of surrogate, leading to lasting symptoms of psychological distress; 2) clinicians are poorly trained in communicating prognosis after SABI, often doing so with variability and bias, inadequately preparing families for their decisions; 3) patients often receive burdensome treatments that they would not choose.

Decision aids improve the quality of patients' decisions based on a large evidence-base, but no empirically validated tools currently exist for surrogate decision-making in SABI patients at high risk for death or disability. This is problematic because surrogates of SABI patients are unprepared for the difficult decisions about the use of life support and patients' potential long-term disability, which hinge on both medical information and the patient's values and preferences. We have developed and refined a tailored digital, web-based decision aid (DA) for families of critically ill SABI patients, conceptually grounded in the Ottawa Decision Support Framework, to enhance, not replace, clinician-family communication. We will leverage a digital platform, which is portable and shareable among family members when geographically distant or not allowed to visit the ICU (as during the COVID-19 pandemic) and allows integration of videos to reach lower-literacy groups. This innovative tool challenges the existing paradigm for decision-making in SABI patients.

This pilot study among 50 surrogates of SABI patients and their clinicians will assess the feasibility of deploying the web-based tool as well as to explore the tools impact on measures of communication and decision-quality.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for surrogates and patients:

  • surrogate is age 18 years or older, no upper age limit;
  • documented surrogate decision-maker (official health care proxy, or legal next of kin) of a critically ill severe acute brain injury (SABI) patient ≥ 3 days after admission;
  • patient is age 18 years or older, no upper age limit;
  • patient has SABI; defined as either traumatic brain injury, spontaneous primary intracerebral hemorrhage (not due to tumor or vascular malformation), or hemispheric acute ischemic stroke;
  • patient is"critically ill" defined as either intubated on a mechanical ventilator, or unable to swallow without a feeding tube (even if not intubated/ventilated);
  • patient is judged by the attending physician to have ≥40% risk of death or long-term functional impairment, elicited by asking the attending physician, "does this patient have at least a 40% chance of in-hospital mortality or long-term functional impairment?", defined as needing assistance with at least 1 activity of daily living (ADL).
  • patient has undergone initial stabilization but remains critically ill;
  • surrogate will participate in clinician-family goals of care meeting, either in person or via video- or telephone-conference.
  • surrogate must be English speaking and literate

Exclusion criteria

for surrogates and patients:

  • devastating patients with severe SABI who die early (within the first 3 days after admission);
  • surrogate decision-maker is non-English speaking;
  • surrogate decision-maker is illiterate.

Inclusion criteria

for clinicians:

  • clinical treating attending, or physician trainee (fellow, resident), or licensed affiliated practitioner who will lead the clinician-family meeting when goals-of-care are discussed;
  • clinician may decline participation in the outcome measures but cannot restrict the surrogate decision-maker in study participation.

Exclusion criteria

for clinicians:

  • unwillingness to comply with study protocol.

Treatment and study plan

Web/mobile/tablet-based digital decision aid + communication (DA+C) tool

Behavioral

The web/mobile/tablet-based digital DA+C toll is designed to enhance communication and shared decision making between clinicians and surrogates of critically ill severe acute brain injury (SABI) with four goals: to 1) prepare families for their surrogate role and discussions with clinicians; 2) provide balanced information to families on prognosis and all available treatment options; 3) provide tailored information about the patient and family to clinicians in advance of family meetings; and 4) serve as a communication guide for clinicians in the clinician-family meeting to facilitate shared decision-making.

Primary outcomes

  1. Feasibility of tool use by surrogate decision-makers

    Time frame: Duration of ICU stay, an expected average of 4 weeks

    Data tracking analytics built into the tool will be employed to determine the extent to which the tools is used as per protocol.

  2. Feasibility of enrolling surrogates in a stepped-wedge (before/after) clinical trial in a neurocritical care setting

    Time frame: Through study completion, estimated 18 months past primary start date

    Measured by meeting target enrollment.

  3. Feasibility of retaining surrogates in a neurocritical care setting

    Time frame: Three-months post SABI

    The number of subjects that complete the long-term follow-up.

Secondary outcomes

  1. Participants' ratings of usability of the tool (Intervention surrogates only)

    Time frame: Duration of ICU stay, an expected average of 4 weeks

    Usability of the tool as measured with the System Usability Scale.

  2. Participants' ratings of perceived effectiveness of the tool in preparing them for decision-making (Intervention surrogates only)

    Time frame: Duration of ICU stay, an expected average of 4 weeks

    Perceived Effectiveness will be measured with an 11-item perceived effectiveness questionnaire using a 5-point Likert scale.

  3. Fidelity to intervention protocol

    Time frame: Through study completion, estimated 18 months past primary start date

    Fidelity to the intervention protocol will be measured using self-checklists by clinicians and review of a random selection of 30% of the audio-recorded clinician-family meetings

Other outcomes

  1. Participants' ratings of what they liked and disliked about the DA+C tool (Intervention surrogates only)

    Time frame: Until right before the scheduled clinician-family meeting, an average of 10-14 days after admission

    Measured by two open ended questions from the Acceptability Scale.

  2. Surrogates' clarity about patient values & preferences

    Time frame: After the scheduled clinician-family meeting, an average of 10-14 days after admission

    We will apply the 3-item Values Clarity Subscale of the Decisional Conflict Scale.

  3. Surrogates' ratings of the degree of shared decision-making

    Time frame: After the scheduled clinician-family meeting, an average of 10-14 days after admission

    We will apply six questions from Quality of Communication Scale pertaining to shared decision-making.

  4. Caregiver Burden

    Time frame: Three-months post SABI

    Measured with the 5-item short form of the Caregiver Burden Scale.

  5. Decision Regret

    Time frame: Three-months post SABI

    Measured using the Decision Regret Scale.

  6. Goals-of-care decision

    Time frame: Hospital discharge up until 3-months post SABI

    Final goals-of-care decision by surrogates (survival vs. withdrawal of life sustaining treatments)

  7. Mortality

    Time frame: Hospital discharge up until 3-months post SABI

    Patient death

  8. Functional status

    Time frame: 3-months post SABI

    We will measure basic activities of daily living with the Glasgow Outcome Scale Extended (GOSE; range 1-8) and the modified Rankin Scale (range 0-6)

  9. Patient-perceived Patient- Centeredness of Care

    Time frame: 3-months post SABI

    To assess patient centeredness of care adapted for use by surrogates

Sponsors and collaborators

Lead sponsor

University of Massachusetts, Worcester

Other

Collaborators

  • Johns Hopkins University
  • National Institute of Nursing Research (NINR)
  • National Institutes of Health (NIH)
  • Worcester Polytechnic Institute

Registry information

Official study title

Pilot Trial of a Web/Mobile/Tablet-based Communication and Goals-of-Care Decision Aid for Clinicians and Families of Severe Acute Brain Injury Patients

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jan 5, 2023
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.